Given the large number of genetic variants previously tested in Caucasian populations deriving from multiple studies (candidate genes and GWAS), we only included genes associated with CAD and already investigated in the GENEMACOR study. In total, we considered 33 genetic variants with a Minor Allele Frequency (MAF) > 2% (Kim et al. 2011), which were distributed by five major physiopathological axes (Table S1), according to their most consensual action pathway in coronary atherosclerosis: six single nucleotide polymorphisms (SNPs) in the lipid metabolism axis corresponding to PSRC1 (rs599839), PCSK9 (rs2114580), KIF6 (rs20455), LPA (rs3798220), ZPR1 (rs964184) and APOE (rs7412/rs429358); nine SNPs in Diabetes/Obesity and Insulin Resistance axis, namely ADIPOQ (rs266729), IGF2BP2 (rs4402960), PPARG (rs1801282), SLC30A8 (rs1326634), TCF7L2 (rs7903146), TAS2R50 (rs1376251), FTO (rs8050136), MC4R (rs17782313) and HNF4A (rs1884613); three SNPs in the Hypertension (Renin-Angiotensin-Aldosterone) axis, namely AGT (rs699), AGT1R (rs5186) and ACE (rs4340); six SNPs were associated with the pro-oxidative state (Oxidation), namely MTHFR (rs1801131 and rs1801133), MTHFD1L (rs6922269), PON1 (rs705379, rs662 and rs854560). Finally, nine SNPs whose pathophysiological mechanism is not fully understood and might be involved in cell cycle, genetic transcription, smooth muscle cells differentiation and proliferation or acting as cotransport binders (Cellular): MIA3 (rs17465637), GJA4 (rs618675), TCF21 (rs12190287), PHACTR1 (rs1332844), ZC3HC1 (rs11556924), CDKN2B-AS1 (rs1333049 and rs4977574), SMAD3 (rs17228212) and ADAMTS7 (rs3825807) (Assimes and Roberts, 2016) (Table S1).

A TaqMan allelic discrimination assay for genotyping was performed using labelled probes and primers pre-established by the supplier (TaqMan SNP Genotyping Assays, Applied Biosystems). All reactions were done on an Applied Biosystems 7300 Real-Time PCR System and genotypes were determined using the 7300 System SDS Software (Applied Biosystems, Foster City, USA) without any prior knowledge of the individual’s clinical data. Quality check of genotyping techniques was maintained by the inclusion of one non-template control (NTC) in each plate of 96 wells. All SNPs TaqMan assays had blind duplicates accounting for 20% of all samples. Some SNP genotypes were randomly confirmed by conventional direct DNA sequencing, as 10-15% of all samples were re-amplified for sequencing.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.